Identification and Validation of Pyroptosis-Related lncRNA Signature and Its Correlation with Immune Landscape in Soft Tissue Sarcomas

Lin, Zhengjun; Xu, Yiting; Zhang, Xianghong; Wan, Jia; Zheng, Tao; Chen, Hongxuan; Chen, Shijie

doi:10.2147/ijgm.s335073

Cited by 2 publications

(3 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, it has been proved that lncRNA could serve as an effective prognostic biomarker for STS. As an example, Lin et al revealed that the pyroptosis-related lncRNAs could accurately predict the clinical prognosis and immune microenvironment of STS ( Lin et al, 2021 ). More importantly, previous studies have confirmed that the NRlncRNA signature also can be used to predict the prognosis of tumors.…”

Section: Discussionmentioning

confidence: 99%

“…There were similar results in the previous studies. Lin et al demonstrated that the STS patients with a lower pyroptosis-related risk score had an upregulated expression of several checkpoints ( Lin et al, 2021 ). Surprisingly, the CIBERSORT algorithm indicated that the risk score and clinical prognosis of STS also were significantly associated with the infiltration of some immune cells.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Necroptosis-Related lncRNA Signature Predicts Prognosis and Indicates the Immune Microenvironment in Soft Tissue Sarcomas

Liu

Feng

2022

Front. Genet.

View full text Add to dashboard Cite

Background: The necroptosis and long noncoding RNA (lncRNA) are critical in the occurrence and development of malignancy, while the association between the necroptosis-related lncRNAs (NRlncRNAs) and soft tissue sarcoma (STS) remains controversial. Therefore, the present study aims to construct a novel signature based on NRlncRNAs to predict the prognosis of STS patients and investigate its possible role.Methods: The transcriptome data and clinical characteristics were extracted from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression database (GTEx). A novel NRlncRNA signature was established and verified by the COX regression analysis and least absolute shrinkage and selection operator (LASSO) regression analysis. Subsequently, the K-M survival analysis, ROC, univariate, multivariate Cox regression analysis, and nomogram were used to evaluate the predictive value of the signature. Also, a variety of bioinformatic analysis algorithms explored the differences between the potential mechanism, tumor immune status, and drug sensitivity in the two-risk group. Finally, the RT-qPCR was performed to evaluate the expression of signature NRlncRNAs.Results: A novel signature consisting of seven NRlncRNAs was successfully established and verified with stable prediction performance and general applicability for STS. Next, the GSEA showed that the patients in the high-risk group were mainly enriched with tumor-related pathways, while the low-risk patients were significantly involved in immune-related pathways. In parallel, we found that the STS patients in the low-risk group had a better immune status than that in the high-risk group. Additionally, there were significant differences in the sensitivity to anti-tumor agents between the two groups. Finally, the RT-qPCR results indicated that these signature NRlncRNAs were abnormally expressed in STS.Conclusion: To the best of our knowledge, it is the first study to construct an NRlncRNA signature for STS. More importantly, the novel signature displays stable value and translational potential for predicting prognosis, tumor immunogenicity, and therapeutic response in STS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A Necroptosis-Related lncRNA Signature Predicts Prognosis and Indicates the Immune Microenvironment in Soft Tissue Sarcomas

Liu

Feng

2022

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…AC006001.2, LINC02585, AL136162.1, AC005041.3, AL023583.1, and LINC02881 are associated with the development of ovarian cancer and involved in regulating pyroptosis in ovarian cancer ( 82 ). LncRNAs involved in the regulation of pyroptosis have been reported in different tumors such as breast cancer, prostate cancer, glioblastoma, head and neck squamous cell carcinoma, soft tissue sarcoma and so on, which are not repeated here ( 83 – 87 ).…”

Section: Pyroptosismentioning

confidence: 99%

LncRNAs and regulated cell death in tumor cells

Wen

Xia

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Regulated Cell Death (RCD) is a mode of cell death that occurs through drug or genetic intervention. The regulation of RCDs is one of the significant reasons for the long survival time of tumor cells and poor prognosis of patients. Long non-coding RNAs (lncRNAs) which are involved in the regulation of tumor biological processes, including RCDs occurring on tumor cells, are closely related to tumor progression. In this review, we describe the mechanisms of eight different RCDs which contain apoptosis, necroptosis, pyroptosis, NETosis, entosis, ferroptosis, autosis and cuproptosis. Meanwhile, their respective roles in the tumor are aggregated. In addition, we outline the literature that is related to the regulatory relationships between lncRNAs and RCDs in tumor cells, which is expected to provide new ideas for tumor diagnosis and treatment.

show abstract

Identification and Validation of Pyroptosis-Related lncRNA Signature and Its Correlation with Immune Landscape in Soft Tissue Sarcomas

Cited by 2 publications

References 44 publications

A Necroptosis-Related lncRNA Signature Predicts Prognosis and Indicates the Immune Microenvironment in Soft Tissue Sarcomas

A Necroptosis-Related lncRNA Signature Predicts Prognosis and Indicates the Immune Microenvironment in Soft Tissue Sarcomas

LncRNAs and regulated cell death in tumor cells

Contact Info

Product

Resources

About